RedScrubs
The Resource for Medical Professionals

In February 2007, I wrote a post in which I described evidence that Lilly’s antipsychotic olanzapine (Zyprexa) was marketed off-label for dementia. The evidence I discussed was based on documents generously and bravely hosted at Furious Seasons. At the time, I was careful to avoid labeling the practices as illegal — they were definitely unethical but I couldn’t really say for sure what if a law was broken. However, a law firm known to represent Lilly was regularly visiting my website at the time, which made me think that Lilly was seriously concerned about legal troubles. I suppose they had good reason to be worried. Read this blog to see why they should be worried and how much money Lilly settled for in their law suit. Off-label marketing of Zyprexa for dementia is downright criminal according to this blogger.